ArticleCancer medicine2026
Safety and Efficacy of Salvage Treatment for Recurrent Nasopharyngeal Carcinoma: A Single-Center Retrospective Study Over 10 Years.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chelerythrine: a novel candidate for targeting miR-21/PTEN/PI3K/AKT in nasopharyngeal carcinoma.Journal of translational medicine · 2026Article
- Safety and Efficacy of Salvage Treatment for Recurrent Nasopharyngeal Carcinoma: A Single-Center Retrospective Study Over 10 Years.Cancer medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo analyze survival outcomes and identify prognostic factors in patients with locoregionally recurrent nasopharyngeal carcinoma (NPC) receiving salvage treatment, and to evaluate the safety profile of re-irradiation.
methodsWe retrospectively analyzed clinical data from 95 patients with recurrent NPC (rM0) who were diagnosed and received salvage treatment at the PLA General Hospital between January 2008 and October 2018. Patients were stratified into two treatment groups: the radiotherapy (RT) group (n = 72) and the non-RT group (n = 23).
resultsWith a median follow-up of 37 months (4-100 months), the 3-year overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) rates were 58.7%, 46.2%, and 33.3%, respectively. The corresponding 5-year OS, PFS, and DSS rates were 34.2%, 31.3%, and 11.1%, respectively. Significant differences in survival outcomes were observed between the RT and non-RT groups: OS (43.4% vs. 0%, p < 0.001), PFS (36.2% vs. 0%, p < 0.001), and DSS (16.2% vs. 0%, p = 0.007). Of the tumor-related deaths, 19 (31.1%) were attributed to massive hemorrhage and 18 (29.5%) to distant metastasis. The univariate and multivariate analyses identified re-irradiation as an independent predictor of superior OS and PFS, and salvage surgery as a predictor of OS improvement. Conversely, advanced nodal disease (rN2-3) independently predicted worse OS and PFS, while local and regional recurrence associated with poorer PFS.
conclusionSalvage re-irradiation significantly improves survival outcomes in locoregionally recurrent NPC, whereas advanced nodal disease (rN2-3) independently predicts poor prognosis. Massive hemorrhage and distant metastasis are the most common causes of death.
trial registrationClinical Trial Register: ChiCTR2500098189.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.